BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Monday, April 29, 2024
Home
»
Newsletters
» BioWorld
BioWorld
May 25, 2004
View Archived Issues
Vicuron Stock Takes Tumble On FDA Antifungal Decision
News from the FDA that Vicuron Pharmaceuticals Inc.'s new drug application for anidulafungin does not support a label for esophageal candidiasis sent the company's stock reeling Monday. (BioWorld Today)
Read More
Altus Series C Brings $51M For Phase II Pancreas Drug
Read More
Vertex Receives $21M From Affiliate Of CF Foundation
Read More
Bioniche Growing Manufacturing In Ireland Through $13M In Loans
Read More
Other News To Note
Read More